XenoPort to Release Third Quarter Financial Results on November 4
October 27 2015 - 10:00AM
Business Wire
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will
release its third quarter financial results on November 4, 2015 at
approximately 4:30 p.m. Eastern Time. The company will host a
conference call at 5:00 p.m. Eastern Time that same day to provide
a summary of its financial results and general business updates. A
replay of the call will be available for one week following the
event.
To access the conference call via the Internet, go to
www.XenoPort.com. Please join the call at least 15 minutes prior to
the start to ensure time for any software downloads that may be
required.
To access the live conference call via phone, dial 888-275-3514.
International callers may access the live call by dialing
706-679-1417. The reference number to enter the call is
69703455.
A replay of the conference call will be available for one week
following the event and may be accessed after 8:00 p.m. Eastern
Time that same day via the Internet, at www.XenoPort.com, or via
phone at 855-859-2056 for domestic callers, or 404-537-3406 for
international callers. The reference number to enter the replay of
the call is 69703455.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
commercializing HORIZANT® (gabapentin enacarbil) Extended-Release
Tablets in the United States. XenoPort has entered into a clinical
trial agreement with the NIAAA under which the NIAAA has initiated
a clinical trial evaluating gabapentin enacarbil as a potential
treatment for alcohol use disorder. REGNITE® (gabapentin enacarbil)
Extended-Release Tablets is being marketed in Japan by Astellas
Pharma Inc. XenoPort has granted exclusive world-wide rights for
the development and commercialization of its clinical-stage oral
product candidate, arbaclofen placarbil, to Indivior PLC for all
indications. XenoPort’s other product candidates include XP23829, a
novel fumaric acid ester prodrug that is a potential treatment for
patients with moderate-to-severe chronic plaque-type psoriasis and
potentially for patients with relapsing forms of multiple
sclerosis, and XP21279, a prodrug of levodopa that is a potential
treatment for patients with idiopathic Parkinson's disease.
To learn more about XenoPort, please visit the Web site at
www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151027005727/en/
XenoPort, Inc.Jackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Sep 2023 to Sep 2024